BackScinoPharm Taiwan, Overview

ScinoPharm Taiwan, Receivables

ScinoPharm Taiwan,'s receivables is $370M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$369.72M
↓ 28.33% YoYΔ $-146.18M vs prior year quarter

Peer trimmed avg / median

Loading

ScinoPharm Taiwan, Receivables History

Loading

ScinoPharm Taiwan, vs. peers: Receivables Comparison

Loading

ScinoPharm Taiwan, Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ScinoPharm Taiwan, (1789.TW) FAQ

The latest receivables for 1789.TW is $370M as of June 2026. That compares with $520M in the prior-year period — down 28.3% year over year. Investors often review this figure alongside ScinoPharm Taiwan,'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 1789.TW's receivables moved from $520M to $370M — a 28.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ScinoPharm Taiwan,'s operating scale or balance-sheet position.

A receivables figure of $370M for 1789.TW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 1789.TW's receivables ($370M), review year-over-year change from $520M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.